Veru VERU

NASDAQ VERU

$2.48 -0.10 (-3.87%)

As of: Sep 9, 2026 · 3:59 PM EDT

Key Stats

Market Cap57.86 Mn

P/E115.53

Div. Yield0.00

Add ratio to table…

About

Veru Inc. is a late stage biopharmaceutical company focused on developing novel medicines for cardiometabolic and inflammatory diseases. The company’s pipeline includes enobosarm an oral selective androgen receptor modulator intended to improve body composition when used with GLP1 receptor agonists for obesity and sabizabulin an oral microtubule disruptor being developed to reduce inflammation in atherosclerotic cardiovascular disease. Veru Inc. previously marketed the FC2…

Investment Thesis

▲ Bull case

Veru's enobosarm addresses a critical unmet need in the obesity market by specifically targeting sarcopenic obesity in older patients, a segment representing approximately 30 million adults in the U.S. alone, where current GLP-1 monotherapy causes up to 50% of weight loss from lean mass, increasing risks of physical function decline, frailty, and hospitalization. The Phase IIb quality study demonstrated enobosarm's ability to reduce stair climb power decline—a validated predictor of mobility disability and mortality—by 59.8% relative reduction at the 3mg dose versus placebo plus semaglutide, directly tackling the muscle loss that drives long-term morbidity in this high-risk population. This focus on functional outcomes, not just weight loss, positions enobosarm to capture premium pricing and payer support in a market where payers are increasingly scrutinizing therapies for broader health benefits beyond scale weight, particularly as obesity treatments expand into elderly demographics with comorbidities. The company's strategic emphasis on physical function via objective stair climb testing, endorsed by the European Working Group on Sarcopenia as a primary diagnostic criterion, creates a defensible clinical differentiation that competitors like Lilly and Novo Nordisk are not currently prioritizing in their obesity pipelines, potentially enabling Veru to secure a niche leadership position in sarcopenic obesity therapeutics even if incremental weight loss alone falls short of 5% thresholds.
The ongoing Phase IIb plateau study, with first patient enrolled March 9, 2026 and interim analysis expected in Q1 CY2027, is designed to definitively test enobosarm's ability to overcome the GLP-1 weight loss plateau affecting 88% of patients within one year—a phenomenon where lost muscle mass may trigger increased appetite and caloric intake, stalling further fat reduction. By preserving lean mass and enhancing physical function, enobosarm could elevate basal metabolic rate and sustain calorie expenditure, enabling incremental weight loss beyond the plateau where semaglutide monotherapy fails; the study's 68-week duration and interim lean/fat mass analysis at 36 weeks provide ample opportunity to demonstrate clinically meaningful dual benefits (fat loss + muscle preservation) that would support a label claim for combination therapy. Success here would not only validate enobosarm's mechanism but also create a catalyst for partnership discussions with major GLP-1 players, as the data could enable label expansion for oral semaglutide/enobosarm fixed-dose combinations—a path Veru highlighted as feasible given its clinical experience with injectable semaglutide, thereby reducing developmental risk and accelerating commercialization timelines versus de novo oral agent development.
Financially, Veru has significantly strengthened its balance sheet through non-dilutive monetization of non-core assets, including the $974,000 gain on ENTADFI asset sale in Q2 FY26 and cumulative $1.7 million gain in H1 FY26, alongside $3.9 million in increased fair value from Onconetix equity securities during Q2 FY26 driven by antidilution provisions post-reverse stock split, all contributing to reduced net losses ($3.1M Q2 FY26 vs $7.9M Q2 FY25) and improved cash positioning ($27.6M cash balance as of March 31, 2026, up from $15.8M September 30, 2025). The October 2025 underwritten public offering yielding $23.4 million net proceeds—structured with prefunded and accompanying warrants—provides ample runway to fund operations through the Phase IIb plateau interim analysis without immediate dilution pressure, while ongoing cost controls (R&D down to $3.1M Q2 FY26 from $3.9M prior quarter; SG&A down to $4.1M from $5.2M) reflect disciplined capital allocation toward value-creating clinical milestones rather than speculative spending, ensuring that cash reserves are strategically deployed to derisk the plateau study outcome which could unlock substantial partnership value or Phase III funding opportunities upon positive readout.

Veru's enobosarm addresses a critical unmet need in the obesity market by specifically targeting sarcopenic obesity in older patients, a segment representing approximately 30 million adults in the U.S. alone, where current GLP-1 monotherapy causes up to 50% of weight loss from lean mass, increasing risks of physical function decline, frailty, and hospitalization. The Phase IIb quality study demonstrated enobosarm's ability to reduce stair climb power decline—a validated predictor of mobility disability and mortality—by 59.8% relative reduction at the 3mg dose versus placebo plus semaglutide, directly tackling the muscle loss that drives long-term morbidity in this high-risk population. This focus on functional outcomes, not just weight loss, positions enobosarm to capture premium pricing and payer support in a market where payers are increasingly scrutinizing therapies for broader health benefits beyond scale weight, particularly as obesity treatments expand into elderly demographics with comorbidities. The company's strategic emphasis on physical function via objective stair climb testing, endorsed by the European Working Group on Sarcopenia as a primary diagnostic criterion, creates a defensible clinical differentiation that competitors like Lilly and Novo Nordisk are not currently prioritizing in their obesity pipelines, potentially enabling Veru to secure a niche leadership position in sarcopenic obesity therapeutics even if incremental weight loss alone falls short of 5% thresholds.
The ongoing Phase IIb plateau study, with first patient enrolled March 9, 2026 and interim analysis expected in Q1 CY2027, is designed to definitively test enobosarm's ability to overcome the GLP-1 weight loss plateau affecting 88% of patients within one year—a phenomenon where lost muscle mass may trigger increased appetite and caloric intake, stalling further fat reduction. By preserving lean mass and enhancing physical function, enobosarm could elevate basal metabolic rate and sustain calorie expenditure, enabling incremental weight loss beyond the plateau where semaglutide monotherapy fails; the study's 68-week duration and interim lean/fat mass analysis at 36 weeks provide ample opportunity to demonstrate clinically meaningful dual benefits (fat loss + muscle preservation) that would support a label claim for combination therapy. Success here would not only validate enobosarm's mechanism but also create a catalyst for partnership discussions with major GLP-1 players, as the data could enable label expansion for oral semaglutide/enobosarm fixed-dose combinations—a path Veru highlighted as feasible given its clinical experience with injectable semaglutide, thereby reducing developmental risk and accelerating commercialization timelines versus de novo oral agent development.
Financially, Veru has significantly strengthened its balance sheet through non-dilutive monetization of non-core assets, including the $974,000 gain on ENTADFI asset sale in Q2 FY26 and cumulative $1.7 million gain in H1 FY26, alongside $3.9 million in increased fair value from Onconetix equity securities during Q2 FY26 driven by antidilution provisions post-reverse stock split, all contributing to reduced net losses ($3.1M Q2 FY26 vs $7.9M Q2 FY25) and improved cash positioning ($27.6M cash balance as of March 31, 2026, up from $15.8M September 30, 2025). The October 2025 underwritten public offering yielding $23.4 million net proceeds—structured with prefunded and accompanying warrants—provides ample runway to fund operations through the Phase IIb plateau interim analysis without immediate dilution pressure, while ongoing cost controls (R&D down to $3.1M Q2 FY26 from $3.9M prior quarter; SG&A down to $4.1M from $5.2M) reflect disciplined capital allocation toward value-creating clinical milestones rather than speculative spending, ensuring that cash reserves are strategically deployed to derisk the plateau study outcome which could unlock substantial partnership value or Phase III funding opportunities upon positive readout.

▼ Bear case

Veru's clinical strategy remains overly reliant on demonstrating incremental weight loss greater than 5% as a primary endpoint for enobosarm in combination with GLP-1 agonists, a benchmark the company itself acknowledges may not be achievable based on Phase IIb quality study trends where fat loss augmentation was observed but not quantified as total weight loss superiority over semaglutide alone; if the Phase IIb plateau study fails to show >5% incremental weight loss at 68 weeks, Veru would need to pivot to functional or bone mineral density endpoints, which carry higher regulatory uncertainty as the FDA has only recently endorsed BMD as a fracture surrogate (December 2025) and has not established clear benchmarks for meaningful physical function improvement in obesity trials, potentially delaying approval and increasing Phase III trial size, cost, and complexity beyond current cash runway projections.
The sarcopenic obesity market, while cited as 30 million U.S. adults, lacks validated diagnostic criteria and standardized reimbursement pathways, with no current ICD-10-CM code specific to sarcopenic obesity and limited payer recognition of physical function as a distinct treatable outcome—meaning payers may reimburse enobosarm only if tied to weight loss indications, where it would compete directly with entrenched GLP-1 monopolies (Lilly and Novo Nordisk treating >98% of the obese population) without clear differentiation in efficacy, especially given that enobosarm's Phase IIb quality study showed only a 44.1% relative reduction in stair climb decline at 6mg versus 59.8% at 3mg, suggesting a non-monotonic dose-response that raises questions about optimal dosing and consistent biological effect, undermining confidence in predictable clinical benefit across the target population.
Ongoing cash burn remains substantial despite recent improvements, with $15.1 million used in operating activities over H1 FY26 and no near-term profitability in sight, as the company continues to rely on non-recurring gains from asset sales (ENTADFI, FC2) and equity revaluations (Onconetix) to offset core losses—these one-time inflows are non-sustainable and mask underlying operational weakness, particularly as the Phase IIb plateau study will require significant additional investment to reach interim analysis, and any delay in enrollment or readout beyond Q1 CY2027 would exacerbate cash pressure given the $27.6 million balance (which includes restricted cash) must cover not only trial costs but also SG&A, debt obligations, and potential CMC scaling for future combinations, leaving minimal buffer for setbacks in a capital-intensive biotech environment where failure to meet clinical milestones often triggers severe valuation compression and dilutive rescue financing.

Veru's clinical strategy remains overly reliant on demonstrating incremental weight loss greater than 5% as a primary endpoint for enobosarm in combination with GLP-1 agonists, a benchmark the company itself acknowledges may not be achievable based on Phase IIb quality study trends where fat loss augmentation was observed but not quantified as total weight loss superiority over semaglutide alone; if the Phase IIb plateau study fails to show >5% incremental weight loss at 68 weeks, Veru would need to pivot to functional or bone mineral density endpoints, which carry higher regulatory uncertainty as the FDA has only recently endorsed BMD as a fracture surrogate (December 2025) and has not established clear benchmarks for meaningful physical function improvement in obesity trials, potentially delaying approval and increasing Phase III trial size, cost, and complexity beyond current cash runway projections.
The sarcopenic obesity market, while cited as 30 million U.S. adults, lacks validated diagnostic criteria and standardized reimbursement pathways, with no current ICD-10-CM code specific to sarcopenic obesity and limited payer recognition of physical function as a distinct treatable outcome—meaning payers may reimburse enobosarm only if tied to weight loss indications, where it would compete directly with entrenched GLP-1 monopolies (Lilly and Novo Nordisk treating >98% of the obese population) without clear differentiation in efficacy, especially given that enobosarm's Phase IIb quality study showed only a 44.1% relative reduction in stair climb decline at 6mg versus 59.8% at 3mg, suggesting a non-monotonic dose-response that raises questions about optimal dosing and consistent biological effect, undermining confidence in predictable clinical benefit across the target population.
Ongoing cash burn remains substantial despite recent improvements, with $15.1 million used in operating activities over H1 FY26 and no near-term profitability in sight, as the company continues to rely on non-recurring gains from asset sales (ENTADFI, FC2) and equity revaluations (Onconetix) to offset core losses—these one-time inflows are non-sustainable and mask underlying operational weakness, particularly as the Phase IIb plateau study will require significant additional investment to reach interim analysis, and any delay in enrollment or readout beyond Q1 CY2027 would exacerbate cash pressure given the $27.6 million balance (which includes restricted cash) must cover not only trial costs but also SG&A, debt obligations, and potential CMC scaling for future combinations, leaving minimal buffer for setbacks in a capital-intensive biotech environment where failure to meet clinical milestones often triggers severe valuation compression and dilutive rescue financing.

Peer group

Peer Comparison

Companies in the Pharmaceuticals

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	JNJ	Johnson & Johnson	primary	643.26 Bn	30.58	6.57	60.73 Bn
2	ABBV	AbbVie Inc.	primary	443.31 Bn	70.19	6.89	70.82 Bn
3	MRK	Merck & Co., Inc.	primary	364.74 Bn	115.10	5.48	53.91 Bn
4	NVS	Novartis Ag	primary	266.46 Bn	9.25	3.88	9.59 Bn
5	PFE	Pfizer Inc	primary	158.57 Bn	36.30	2.49	63.19 Bn
6	SNY	Sanofi	primary	52.33 Bn	11.23	0.98	25.19 Bn
7	RVMD	Revolution Medicines, Inc.	primary	43.79 Bn	-24.76	-	-
8	INCY	Incyte Corp	primary	25.23 Bn	15.65	4.34	0.04 Bn

Veru VERU

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password